Drug intelligence / Profile preview

RK007

Development stage: Preclinical
Lead developer: RevolKa
Modality: Recombinant Proteins and Enzymes

Overview

RK007 is a protein-based therapeutic candidate developed by RevolKa, a biotechnology company that utilizes a proprietary protein engineering platform. The drug is part of RevolKa's internal pipeline, which leverages AI and directed evolution to create optimized proteins. As of early 2024, the specific molecular target and therapeutic indication for RK007 remain undisclosed by the company, although it is categorized under their protein modality programs. The development status is listed as "Undisclosed (Completed)" in company materials, suggesting the completion of early-stage research or technology validation.

Beyond the preview

Go deeper on RK007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RK007.

Explore the full profile